Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results